JRSM >
Volume 99, Number 5 >
Pp. 245-249
Wrexham Academic Unit, Wales College of Medicine, Cardiff University, Wales, UK
Correspondence to: Dr J N Harvey, Senior Lecturer in Diabetes, Endocrinology and Metabolism, Gladstone Centre, Maelor Hospital, Wrexham LL13 7TD, Wales, UK E-mail: john.harvey{at}new-tr.wales.nhs.uk
 | SUMMARY |
|---|
 TOP SUMMARY INTRODUCTIONMETHODSRESULTSCOMMENTREFERENCES |
|---|
Design Observational study.
Participants Three generations of an affected kindred.
Intervention None.
Main outcome measures Neurological features suggestive of adrenoleukodystrophy or adrenomyeloneuropathy. Measurement of very long chain fatty acids. Molecular analysis of the adrenoleukodystrophy gene.
Results Three adults presented with adrenomyeloneuropathy and two children with adrenoleukodystrophy. Circulating concentrations of long chain fatty acids were raised consistent with clinical features. A mutation in exon 6 of the adrenoleukodystrophy gene (P543L) was identified. This had not previously been identified but has subsequently been reported by other groups.
Conclusions Adrenomyeloneuropathy should be considered in the differential diagnosis in male patients presenting with adrenal failure. Early diagnosis allows genetic counselling in such families and may become more important as treatment strategies evolve.
| INTRODUCTION |
|---|
|
TOPSUMMARYINTRODUCTIONMETHODSRESULTSCOMMENTREFERENCES |
|---|
| METHODS |
|---|
|
TOPSUMMARYINTRODUCTIONMETHODSRESULTSCOMMENTREFERENCES |
|---|
|
Molecular genetic analysis: Leucocyte DNA was extracted by standard methods. SSCP analysis of each of the exons of the adrenoleukodystrophy gene suggested a mutation in exon 6. Direct sequencing of both strands of an exon 6 PCR product was undertaken.
| RESULTS |
|---|
|
TOPSUMMARYINTRODUCTIONMETHODSRESULTSCOMMENTREFERENCES |
|---|
In 1995 he presented with acute urinary retention: cystoscopy was normal. From 1996 he complained of calf muscle pain and weakness, symptoms which were exacerbated by exercise. This progressively worsened and neurological assessment in 1998 identified a spastic diplegia associated with reduced sensation to vibration, light touch and pinprick. Serological tests for syphilis and borelia were negative. Serum folate and B12 levels were normal. Cerebrospinal fluid showed no oligoclonal bands and magnetic resonance imaging of spine was normal. Nerve conduction studies revealed a demyelinating motor neuropathy. The diagnosis of adrenomyeloneuropathy was confirmed by raised circulating concentrations of very long chain fatty acids (VLCFA) (Table 1). The neuropathic pain increased and he developed myoclonus. In 2002 he was wheelchair bound with an indwelling urinary catheter. Subsequently he has developed features of a dementia of frontal lobe type.
|
Case II-3
The index case had three brothers
(Figure 1) who were invited for
assessment after the first diagnosis was made. His twin brother
(non-identical) was seen at age 39 and gave an 18 month history of
paraesthesiae in both legs but no weakness. He had no abnormal pigmentation or
postural drop of blood pressure. Muscle tone was increased with brisk reflexes
on the left. Sensation of light touch and pinprick was impaired on the soles
of both feet. A short synacthen test showed cortisol 258 nmo/l at baseline,
rising to 323 nmol/l at 30 min and 386 nmol/l at 60 min. Glucocorticoid
replacement therapy was started. There has been no further clinically evident
neurological deterioration on follow up.
Case II-2
This older brother described paraesthesiae in both legs. For 2 years he had
been occasionally stumbling or tripping and his legs sometimes felt stiff. He
complained of dizziness on standing and was easily tired. There was no
abnormal pigmentation or postural drop in blood pressure.
Reflexes were brisk with left ankle clonus demonstrable. He had lost sensation to vibration, light touch and pin prick up to the knees. A short synacthen test was abnormal, with cortisol 300 nmol/L at baseline, 266 at 30 min and 289 at 60 min. Glucocorticoid replacement was initiated. This patient underwent formal neuropsychological and neurophysiological testing. Intellectual and memory functions were within the normal range. Somatosensory evoked potentials showed mild delay in latency in tibial and median nerves suggestive of delay in central transmission of impulses through spinal cord and brain. Brainstem auditory evoked potentials were not clearly abnormal. Visual evoked potentials showed abnormal latency in the left eye. The overall picture was of mild central demyelination. There has been no clinically evident neurological deterioration on follow up.
Case II-1
The patient chose not to have any investigations as he had only two sons
who could not be affected.
Childhood-onset adrenoleukodystrophy: Case IV-1
The first affected grandchild (Figure
1) was born in 1997. He was tested electively in 2000 after the
diagnosis of adrenomyeloneuropathy was made in his maternal grandfather. At
this time he was asymptomatic.
Increased VLCFA (very long-chain fatty acids) were found and the presence
of the same genetic mutation (P543L) was confirmed. In 2001 he had an abnormal
short synacthen test and was commenced on glucocorticoid replacement. His
baseline cortisol was 246nmol/L. After 250 g of synacthen, his 30 min cortisol
was 284 nmol/L, with a 60 min result of 282 nmol/L. At the age of 2
years formal assessment of speech and language confirmed developmental delay.
His motor development was within normal limits. Visual assessment at age 3
revealed a right convergent squint but nothing else. Visual evoked potentials
were normal 15 months later. Weight and height were within the normal range
for his age.
From age 61/2 it was noted that speech and language development was becoming more delayed with increasing behavioural problems. Regression of gross motor function was noted with increasing dyspraxia. Formal neurological examination was otherwise normal. Assessment by an educational psychologist led to placement in a special school. In 2004 a magnetic resonance imaging scan of the brain showed some early abnormalities. In light of this, and evidence of learning difficulties, he underwent bone marrow transplantation, but subsequently developed graft versus host disease and died.
Case IV-2
The younger affected grandchild was born in 2001. An antenatal diagnosis
was made at 10 weeks gestation on chorionic villus sampling. At the time the
parents were uncertain as to whether the pregnancy would be continued if
positive. In March 2003 a short synacthen test was abnormal and he has
required regular glucocorticoid replacement. Salivary cortisols showed values
of 165 nmol/L at baseline, 150 nmol/L at 10 min, 135nmol/L at 20 min, 120
nmol/L at 30 min and 150 nmol/L at 40 min. At last assessment aged 3, growth
and development were normal, with no abnormal neurological signs. Visual
evoked potentials were also normal. Magnetic resonance imaging of brain in
2004 was normal.
The family have been advised by clinical genetics services. This child has also been tissue typed in case of neurological deterioration at which point bone marrow transplantation may be indicated.
Biochemistry
The VLCFA results are given in Table
1.
Molecular genetics
Direct sequencing of both strands of an exon 6 PCR product identified the
mutation P543L. This gene variant introduces a novel Pst 1 site (there is
another Pst 1 site in exon 6 of the gene which acts as an internal control for
digestion). The P543L mutation was shown to be present in each of the 3
brothers (cases II-2, II-3 and II-4) and the 2 grandchildren (cases IV-1 and
IV-2) described above. At the time we first identified this mutation it had
not been reported elsewhere in the literature.
| COMMENT |
|---|
|
TOPSUMMARYINTRODUCTIONMETHODSRESULTSCOMMENTREFERENCES |
|---|
Biochemistry
The gene in question (ABCD1) codes for a peroxisomal membrane protein,
adrenoleukodystrophy protein (ADLP), which is a member of the adenosine
triphosphate binding cassette (ABC) transporter
superfamily.3
Saturated VLCFA such as tetracosanoic (C24:0) and hexacosanoic acid (C26:0)
accumulate in brain, adrenal glands and
plasma.5 This
accumulation is associated with failure of peroxisomal very long chain fatty
acyl CoA synthetase to initiate degradation by beta-oxidation. The abnormally
high levels of VLCFA impair the stability of biological
membranes.6 The
abnormal gene is located in the Xq28 region. It consists of approximately 26
kilobases of DNA and encodes an mRNA of 4.3 kb and a protein of 745 amino
acids.3 Over 500
mutations have been
identified.1 Of
these, 59% are missense mutations, 23% frame shifts, 10% are nonsense
mutations, 5% are in-frame deletions-insertions and 4% are large
deletions.6 The
website
[www.x-ald.nl]
updates the mutations identified worldwide. The mutation identified here was
first reported in an Italian family and subsequently in three Spanish
families.7,8
It has been shown to inhibit expression of ADLP in cultured fibroblasts from
affected
patients.8
Clinical presentation
The adult onset form of the disease itself shows a wide range of phenotypic
variability ranging from pure adrenomyeloneuropathy with neurological signs
that are confined to the spinal cord and peripheral nerves to forms with
variable cerebral involvement. Pure myelopathy, cerebral involvement or
adrenal failure may occur alone. The mutation described here predisposes to
both adrenoleukodystrophy and adrenomyeloneuropathy.
A single mutation may cause different phenotypes not only in unrelated patients but also within the same family.1,5 The reason for the phenotypic variability and variable age of presentation of adrenomyeloneuropathy/adrenoleukodystrophy is unknown. Modifier genes1,3,4 or environmental factors have been suggested.9
An Italian series of cases of idiopathic primary adrenal failure found 4/19 male patients (21%) who developed adrenal failure aged 14-36 years had adrenomyeloneuropathy/adrenoleukodystrophy.2 Of these four, two had no neurological signs 6-29 years after the diagnosis of adrenal failure. But magnetic resonance imaging showed cerebral involvement or spinal atrophy in all four and electrophysiological studies were abnormal. In boys with primary adrenal failure 50% of cases are due to adrenoleukodystrophy. In patients known to have adrenoleukodystrophy/adrenomyeloneuropathy, 90% of male children and 65% of adults will have impaired adrenal function. Abnormalities on examination or investigation, usually adrenomyeloneuropathy, can be found in 50% of female carriers.1
Diagnosis
Features suggestive of the diagnosis of
adrenomyeloneuropathy/adrenoleukodystrophy are:
Adult patients should be assessed for long tract signs. These may be subtle or absent. Measurement of VLCFA levels is diagnostic of adrenomyeloneuropathy in adults. Other peroxisomal disorders may elevate levels in the young (e.g. Zellweger's syndrome, infantile Refsum's disease, neonatal adrenoleukodystrophy). Such a diagnosis has implications for the family and prenatal testing can be offered after appropriate genetic counselling. Molecular genetic analysis is recommended and in the UK is available from the Molecular Genetics Laboratory at Liverpool Women's Hospital. In the Spanish series, study of 62 affected families revealed 53 different mutations.8 In three patients (5%) no mutation was identified despite raised VLCFA and negative ADLP expression.
Management
Includes surveillance of neurological and endocrine function. Magnetic
resonance imaging scans and neuropsychological testing may be used for
monitoring. No clearly effective treatment based on influencing lipid
metabolism has yet emerged although Lorenzo's oil (4:1 glyceryl trioleate and
glyceryl trierucate) administered before the age of 6 may reduce the
probability of developing neurological deficit in later
life.1 Statins
reduce circulating levels of VLCFAs but have not yet been shown to influence
neurological or endocrine function. Bone marrow transplantation is an option
in boys with early neurological features, abnormal magnetic resonance imaging
scans and neuropsychological dysfunction but is not recommended in the
severely affected group (i.e. performance IQ<80) and has a significant
morbidity and
mortality.10
Survival data are superior to those not transplanted with improvement in
neurological function, magnetic resonance imaging scans and neuropsychological
measurements.11
Patients up to the age of 20 have been
transplanted.12
| Footnotes |
|---|
| REFERENCES |
|---|
|
TOPSUMMARYINTRODUCTIONMETHODSRESULTSCOMMENTREFERENCES |
|---|
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
Related articles in JRSM:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
